FINWIRES · TerminalLIVE
FINWIRES

Dutch Bros Faces Tangible Same-Store Sales Catalysts That Are Positioned to Remain Powerful, Oppenheimer Says

By

Dutch Bros (BROS) faces tangible same-store sales catalysts that are positioned to remain powerful, with current consensus margin forecasts appearing to be conservatively modeled, Oppenheimer said in a Tuesday note.

Oppenheimer said it continues to have an upside bias to Wall Street's 2026 same-store sales estimate of 5.7%, noting the company's food roll-out all company units accelerating in Q3, as well as the new Myst platform launched in May.

The company's 2027 coffee costs would be down 20% if current prices hold, Oppenheimer said, adding that this, along with more moderate food, rent headwinds positions 2027 margins for upside compared with Wall Street's estimate.

Oppenheimer raised its 2026 to 2028 earnings before interest, taxes, depreciation, and amortization estimates to $378.8 million, $479.8 million, and $594.7 million from $375.5 million, $470.5 million and $582.2 million, respectively.

Oppenheimer raised its price target to $82 from $72 and reiterated its outperform rating.

Price: $72.40, Change: $+0.70, Percent Change: +0.98%

Related Articles

Wire

Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial

Genmab (GMAB) said that a Phase 3 study of epcoritamab combined with lenalidomide met its primary objective, helping adults with relapsed or refractory diffuse large B-cell lymphoma stay progression-free longer than those receiving standard therapy.The regimen cut the risk of disease progression or death by 60% under US censoring rules and 56% under censoring rules used outside the US, with both results statistically significant, Genmab said Monday in a statement.Genmab said the safety profile was consistent with what's known for each drug. The company and its partner, AbbVie (ABBV), plan to discuss the findings with global regulators.The ongoing Phase 3 trial is enrolling adults who received at least one prior systemic therapy and were not eligible for stem-cell transplant or CAR-T treatment.Genmab shares rose 2.2% in after-hours trading, and AbbVie eased 0.2%.

$ABBV$GMAB
Wire

Mama's Creations Commences Proposed Common Stock Offering

Mama's Creations (MAMA) said late Monday it has commenced a proposed, underwritten public offering of its common stock.The company said it plans to grant the underwriters a 30-day option to buy up to an additional 15% of the shares offered.It intends to use the offering net proceeds for working capital and general corporate purposes, the company added.Shares of Mama's Creations were down more than 10% in after-hours activity.

$MAMA
Wire

Concentrix Fiscal Q2 Earnings Fall, Revenue Rises; FY Outlook Cut; Shares Tumble After Hours

Concentrix (CNXC) reported fiscal Q2 non-GAAP net income late Monday of $2.63 per diluted share, down from $2.70 a year earlier.Four analysts polled by FactSet expected $2.64.Revenue in the three months ended May 31 rose to $2.46 billion from $2.42 billion a year earlier.Four analysts expected $2.47 billion.Concentrix expects fiscal Q3 non-GAAP EPS of $2.65 to $2.77 on revenue of $2.47 billion to $2.49 billion.Four analysts project EPS of $3.09 on revenue of $2.53 billion.The company lowered full-year EPS guidance to $10.83 to $11.18 on revenue of $9.93 billion to $10.03 billion. The previous forecast pegged EPS at $11.48 to $12.07 on revenue of $10.04 billion to $10.18 billion.Four analysts expect EPS of $11.71 on revenue of $10.11 billion.Concentrix shares fell 26% in after-hours trading.The company maintained its quarterly dividend of $0.36 a share, payable Aug. 4, to stockholders of record July 24.

$CNXC